Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
adeno-associated virus tRNA glycine (AAV-tRNA-Gly) is an investigational gene therapy designed to treat Charcot-Marie-Tooth disease type 2D (CMT2D), a progressive neuromuscular disorder. CMT2D is caused by dominant mutations in the GARS1 gene, which encodes glycyl-tRNA synthetase (GlyRS). The mutant GlyRS enzyme binds to tRNA Gly with abnormally high affinity and fails to release it, leading to tRNA Gly sequestration, ribosome stalling, activation of the integrated stress response (ISR), and axonal degeneration. Developed by XtRNA Bio (a spinout from Radboud University), AAV-tRNA-Gly utilizes an adeno-associated virus vector to deliver genetic instructions that elevate cellular tRNA Gly levels. This supplementation restores normal protein synthesis, suppresses ISR activation, and has been shown in preclinical models to prevent and reverse peripheral neuropathy.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on adeno-associated virus tRNA glycine.
Work on adeno-associated virus tRNA glycine? Claim this page to correct or add information. Claim this page